CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
Eli Lilly and Company
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Celgene
Sumitomo Pharma America, Inc.
Incyte Corporation
Oncternal Therapeutics, Inc
Novartis
Pharmacyclics LLC.
Pharmacyclics LLC.
Pharmacyclics LLC.
Pharmacyclics LLC.
Janssen Research & Development, LLC
AstraZeneca
Pharmacyclics LLC.
Pharmacyclics LLC.